Verve Therapeutics Shares Fall 14%, Company Commences Public Offering
21 July 2022 - 7:52AM
Dow Jones News
By Stephen Nakrosis
Shares of Verve Therapeutics, Inc. were lower in Wednesday's
late trading market after the company said it commenced an
underwritten public offering of $200 million of common stock.
All shares are being offered by Verve, the company said.
At 5:09 p.m. EDT, the company's shares had fallen 14.45% to
trade at $30.72 per share. The stock finished the day's regular
session with an 11.21% gain at $35.91 per share.
Also on Wednesday, the company said it entered a global research
collaboration with Vertex Pharmaceuticals, Inc. to discover and
develop an in vivo gene editing program for a single undisclosed
liver disease.
Verve has a market cap of $1.57 billion, 48.66 million shares
outstanding and a public float of 25.05 million shares.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
July 20, 2022 17:37 ET (21:37 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Vertex Pharmaceuticals (NASDAQ:VRTX)
Historical Stock Chart
From Apr 2024 to May 2024
Vertex Pharmaceuticals (NASDAQ:VRTX)
Historical Stock Chart
From May 2023 to May 2024